Novo Nordisk shares climbed on Wednesday after the Danish drugmaker raised its full-year guidance. The company cited strong demand for its new weight-loss pill launched earlier this year.
The guidance increase signals confidence in the oral version of Wegovy as a growth driver. Novo has faced mounting pressure from competitors and uneven sales in the weight-loss market.
Investors responded positively to the update, sending the stock higher during the session. The pill format could broaden access for patients who prefer not to use injectable treatments.
Novo has invested heavily in expanding production capacity for its obesity drugs. Supply constraints have eased in some markets, supporting faster adoption of the new pill.
The company also faces pricing pressure and rising competition from rival treatments. Still, the raised forecast suggests underlying demand remains robust.
Analysts viewed the guidance hike as a reassuring sign for Novo’s near-term outlook. The oral option may help the company reach patients earlier in their treatment journey.
Novo plans to report full quarterly results later this month. Investors will watch for details on prescription trends and manufacturing scale-up.
